Design Therapeutics, Inc.
Design Therapeutics, Inc. (DSGN): 17 pipeline candidates · 5 upcoming catalysts · ~39 mo cash runway · 14 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
39.0 months
D/E 0.06 · 0% dilution
Lead: Approved
17 candidates
5 upcoming, next in ~132d
N/A
A transparent, data-derived signal for Design Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$685.2M
Cash
$12.8M
Quarterly Burn
$16.4M
Runway
39.0 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (17 candidates)
| Drug | Phase |
|---|---|
| 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use | Phase 1 |
| Abiraterone - Study | Phase 3 |
| Abiraterone - Usual | Phase 3 |
| Alectinib - Study | Phase 3 |
| Alectinib - Usual | Phase 3 |
| bupropion | Approved |
| Combination of MK3475 with Metronomic CP | Phase 2 |
| Combination of MK3475 with Metronomic CP and G100 | Phase 2 |
| DT-168 | Phase 2 |
| dt-216p2 | Phase 2 |
Showing 10 of 17 candidates. Sign up for full pipeline.
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
120
Total value held
$267.2M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 2,972,973 | $31.6M |
| vanguard capital management llc | 2,699,700 | $28.7M |
| baker bros. advisors lp | 2,585,978 | $27.5M |
| blackrock, inc. | 2,133,764 | $22.7M |
| woodline partners lp | 1,923,002 | $20.5M |
| driehaus capital management llc | 1,744,987 | $18.6M |
| trails edge capital partners, lp | 852,013 | $9.1M |
| fmr llc | 798,411 | $8.5M |
| kynam capital management, lp | 784,606 | $8.3M |
| geode capital management, llc | 692,518 | $7.4M |
Showing top 10 of 120 institutional holders of Design Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Design Therapeutics, Inc.'s pipeline?
Design Therapeutics, Inc. (DSGN) has 17 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Design Therapeutics, Inc.'s lead drug candidate?
Design Therapeutics, Inc.'s most advanced tracked candidate is 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use (Phase 1) for HIV Infections.
What is Design Therapeutics, Inc.'s next catalyst?
Design Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Explore the Relationship Between Single Nucleotide Polymorphisms and Topotecan Response and Toxicity" — expected October 28, 2026.
What is Design Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Design Therapeutics, Inc. has approximately 39.0 months of cash runway.
What is Design Therapeutics, Inc.'s market capitalization?
Design Therapeutics, Inc.'s market capitalization is approximately $685.2M.
Get the full picture on Design Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.